ARK Genomic Revolution ETF (BATS:ARKG) Hits New 12-Month High – What’s Next?

ARK Genomic Revolution ETF (BATS:ARKG) shares hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $53.41 and last traded at $52.87, with a volume of 3481280 shares trading hands. The stock had previously closed at $51.81.

ARK Genomic Revolution ETF Stock Performance

The business has a 50-day moving average price of $44.98 and a 200 day moving average price of $36.72.

Institutional Investors Weigh In On ARK Genomic Revolution ETF

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in shares of ARK Genomic Revolution ETF by 49.7% in the fourth quarter. BNP Paribas Financial Markets now owns 3,514,980 shares of the company’s stock worth $101,829,000 after purchasing an additional 1,167,558 shares in the last quarter. Kingsview Wealth Management LLC purchased a new stake in shares of ARK Genomic Revolution ETF in the fourth quarter worth about $5,975,000. Midwest Financial Partners Investments Inc. lifted its holdings in shares of ARK Genomic Revolution ETF by 2.1% in the first quarter. Midwest Financial Partners Investments Inc. now owns 209,416 shares of the company’s stock worth $5,533,000 after buying an additional 4,230 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of ARK Genomic Revolution ETF by 0.3% in the second quarter. Baird Financial Group Inc. now owns 73,722 shares of the company’s stock valued at $3,101,000 after acquiring an additional 255 shares during the period. Finally, HighTower Advisors LLC boosted its position in shares of ARK Genomic Revolution ETF by 5.1% in the fourth quarter. HighTower Advisors LLC now owns 98,802 shares of the company’s stock valued at $2,862,000 after acquiring an additional 4,811 shares during the period.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.